In this study, fermented products of yeast and acetic acid bacteria were prepared using coffee bean extracts, and evaluated the fermentation characteristics and functionality of fermented products respectively. Roasted coffee extract was manufactured mixed solution (70% coffee extract, 20% glucose, 1% yeast extract) for yeast fermentation with Saccharomyces cerevisiae SRCM102539 and fermented for 5 days. During the yeast fermentation period (5 days), the live cell counts and physicochemical properties (soluble solid content, pH and total acidity), free sugar, organic acid and ethanol contents were analyzed. The live cell counts, soluble solids, pH and total acidity of UFRCE (day 0, unfermented roasted coffee extract) were 4.50 log CFU/mL, 21.27°Brix, 4.99, 0.21%, and FRCE (day 5, fermented roasted coffee extract) were 6.72 log CFU/mL, 7.60°Brix, 4.56, 0.30%, respectively. The organic acids of FRCE were succinic acid (373.00 mg%), acetic acid (190.91 mg%), and citric acid (67.41 mg%), respectively. The glucose content of UFRCE was 23.89% (w/v), but FRCE was not detected. The ethanol content of UFRCE was not detected, but FRCE was detected 8.41% (w/v). The anti-inflammatory effect of UFRCE and FRCE were evaluated in lipopolysaccharide (LPS, 1 μg/mL)-induced inflammatory reactions in RAW 264.7 cells. UFRCE was decreased nitric oxide (NO), prostaglandin2 (PGE2), tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) production in RAW 264.7 cells by 26.01%, 31.70%, 32.31%, 62.10% and FRCE was decreased 41.82%, 55.71%, 40.14%, 71.13%, respectively, at concentration of 0.5 mg/mL. UFRCE were inhibited activation of iNOS and COX-2 expression 50.28%, 20.01% and FRCE were inhibited 58.01%, 41.23%, respectively. FRCE showed higher anti-inflammatory activity than UFRCE, and this activity was increased by yeast fermentation. Roasted coffee liquor (70% coffee extract, 5% glucose, 1% yeast extract, 6% ethanol) was manufactured for seed culture with Acetobacter pasteurianus CT_02 and fermented for 8 days. Acetic acid bacteria fermentation was performed by adding 30% (v/v) of seed culture to coffee wine. During the acetic acid bacteria fermentation period (15 days), the live cell counts and physicochemical properties (soluble solid content, pH and total acidity), free sugar, organic acid and ethanol contents were analyzed. The live cell counts, soluble solids, pH and total acidity of AUFCW (day 0, acetic acid unfermented coffee wine) were 6.35 log CFU/mL, 8.10°Brix, 3.88, 1.29%, and AFCW (day 15, acetic acid fermented coffee wine) were 4.40 log CFU/mL, 8.57°Brix, 3.07, 7.45%, respectively. The organic acids of AFCW were acetic acid (5921.43 mg%), succinic acid (434.94 mg%) and citric acid (69.43 mg%), respectively. The antibacterial activity was increased as the acetic acid fermentation progressed, and AFCW showed the highest antibacterial activity in B. cereus KTCT1661 and S. aureus KCCM11593 strains. The pancreatic lipase inhibitory activity also increased according to the fermentation period, and the 50% inhibitory activity (IC50) values of the fermentation products on the 10th and 15th days were 226.94 and 334.48, respectively, at the dilution factor. The anti-obesity effect of AUFCW and AFCW were evaluated in lipid accumulation rate, leptin protein expression level, and adipogenesis-related genes at the mRNA level. AUFCW was decreased lipid accumulation rate, leptin protein expression in 3T3-L1 cells by 15.66%, 18.80%, and AFCW was decreased 30.63%, 49.80%, respectively, at a concentration of 0.2 mg/mL. AUFCW were inhibited activation of PPAR-γ and SREBP-1c expression 13.47%, 36.75% and AFCW were inhibited 21.84%, 50.79%, respectively. AFCW showed higher antibacterial activity and anti-obesity effect than AUFCW, and these activities were increased by acetic acid bacteria fermentation.
List of figures ⅳList of tables ⅴABSTRACT ⅵⅠ. 서 론 1Ⅱ. 재료 및 방법 41. 재료 42. 시약 및 사용기기 43. 커피 원두 추출물을 이용한 효모 발효 63.1. 커피 추출물 및 혼합액 제조 63.2. 효모 배양 및 발효 64. 커피 효모 발효물의 발효특성 74.1. 생균수 및 이화학적 특성 74.2. 유기산, 유리당 및 에탄올 함량 분석 85. 커피 효모 발효물의 기능성 평가(In vitro) 105.1. 항염증 평가를 위한 시료 제조 105.2. 항염증 활성 평가 105.2.1. RAW 264.7 세포배양 및 독성 평가 105.2.2. Nitric oxide(NO) 및 PGE2 생성량 측정 115.2.3. 전염증성 사이토카인(TNF-α, IL-1β) 생성량 측정 125.2.4. iNOS 및 COX-2 mRNA 수준 발현량 측정 136. 커피 와인을 이용한 초산균의 발효 146.1. 커피 와인 전처리 146.2. 커피 주정주 및 종초 제조 146.3. 커피 초산균 발효 157. 커피 초산균 발효물의 발효 특성 157.1. 생균수 및 이화학적 특성 157.2. 유기산. 유리당 및 에탄올 함량 분석 168. 커피 초산균 발효물의 기능성 평가(In vitro) 188.1. 항균 활성 188.2. Lipase 저해 활성 평가 198.3. 항비만 활성 평가 198.3.1. 항비만 평가를 위한 시료 제조 198.3.2. 3T3-L1 세포배양 및 독성 평가 208.3.3. 3T3-L1 세포 지방분화 유도 218.3.4. Oil-Red-O 염색 및 지질 축적률 평가 218.3.5. 렙틴 단백질 발현량 측정 228.3.6. PPAR-γ 및 SREBP-1c mRNA 수준 발현량 측정 229. 통계분석 23Ⅲ. 결과 및 고찰 241. 커피 효모 발효물의 발효 특성 241.1. 생균수 및 이화학적 특성 변화 241.2. 유리산 함량 변화 261.3. 유리당 및 에탄올의 함량 변화 282. 커피 효모 발효물의 기능성 평가(In vitro) 302.1. 항염증 활성 평가 302.1.1. RAW 264.7 세포 생존율 평가 302.1.2. NO 생성 억제 효과 322.1.3. PGE2 생성 억제 효과 342.1.4. TNF-α 생성 억제 효과 362.1.5. IL-1β 생성 억제 효과 382.1.6. iNOS mRNA 발현 억제 효과 402.1.7. COX-2 mRNA 발현 억제 효과 423. 커피 초산균 발효물의 발효 특성 443.1. 생균수 및 이화학적 특성 443.1.1. 종초 발효 기간 설정 443.1.2. 초산 발효 기간에 따른 변화 463.2. 유리산 함량 변화 483.3. 유리당 및 에탄올의 함량 변화 504. 커피 초산균 발효물의 기능성 평가(In vitro) 524.1. 항균 활성 평가 524.2. Pancreatic lipase 저해 활성 544.3. 항비만 활성 평가 574.3.1. 3T3-L1 세포 생존율 평가 574.3.2. Oil-Red-O 염색 및 지질 축적률 확인 594.3.3. 렙틴 단백질 발현 억제 활성 614.3.4. PPAR-γ mRNA 발현 억제 효과 634.3.5. SREBP-1c mRNA 발현 억제 효과 65Ⅳ. 요약 67Ⅴ. 참고문헌 70